P Simon Jones
Overview
Explore the profile of P Simon Jones including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
2742
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perry A, Hughes L, Adams N, Naessens M, Kloosterman N, Rouse M, et al.
Neuroimage Clin
. 2024 Sep;
44:103671.
PMID: 39305652
The consequences of frontotemporal lobar degeneration include changes in prefrontal cortical neurophysiology, with abnormalities of neural dynamics reported in the beta frequency range (14-30 Hz) that correlate with functional severity....
2.
Malpetti M, Swann P, Tsvetanov K, Chouliaras L, Strauss A, Chikaura T, et al.
Brain
. 2024 Aug;
148(2):493-505.
PMID: 39155063
Neuroinflammation is an important pathogenic mechanism in many neurodegenerative diseases, including those caused by frontotemporal lobar degeneration. Post-mortem and in vivo imaging studies have shown brain inflammation early in these...
3.
Holland N, Savulich G, Jones P, Whiteside D, Street D, Swann P, et al.
Mov Disord
. 2024 Apr;
39(7):1166-1178.
PMID: 38671545
Background/objective: The corticobasal syndrome (CBS) is a complex asymmetric movement disorder, with cognitive impairment. Although commonly associated with the primary 4-repeat-tauopathy of corticobasal degeneration, clinicopathological correlation is poor, and a...
4.
Whiteside D, Holland N, Tsvetanov K, Mak E, Malpetti M, Savulich G, et al.
Nat Commun
. 2023 Dec;
14(1):8458.
PMID: 38114493
There is extensive synaptic loss from frontotemporal lobar degeneration, in preclinical models and human in vivo and post mortem studies. Understanding the consequences of synaptic loss for network function is...
5.
Street D, Bevan-Jones W, Malpetti M, Jones P, Passamonti L, Ghosh B, et al.
Parkinsonism Relat Disord
. 2023 Oct;
116:105866.
PMID: 37804622
Introduction: Many studies of the Richardson's syndrome phenotype of progressive supranuclear palsy (PSP) have elucidated regions of progressive atrophy and neural correlates of clinical severity. However, the neural correlates of...
6.
Ye R, Hezemans F, OCallaghan C, Tsvetanov K, Rua C, Jones P, et al.
J Neurosci
. 2023 Sep;
43(42):7028-7040.
PMID: 37669861
Parkinson's disease (PD) and progressive supranuclear palsy (PSP) both impair response inhibition, exacerbating impulsivity. Inhibitory control deficits vary across individuals and are linked with worse prognosis, and lack improvement on...
7.
Whiteside D, Street D, Murley A, Jones P, Malpetti M, Ghosh B, et al.
Hum Brain Mapp
. 2023 Jun;
44(11):4239-4255.
PMID: 37269181
There is a pressing need to understand the factors that predict prognosis in progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS), with high heterogeneity over the poor average survival. We...
8.
Holland N, Jones P, Savulich G, Naessens M, Malpetti M, Whiteside D, et al.
Mov Disord
. 2023 May;
38(7):1316-1326.
PMID: 37171832
Background: Synaptic loss is characteristic of many neurodegenerative diseases; it occurs early and is strongly related to functional deficits. Objective: In this longitudinal observational study, we determine the rate at...
9.
Cope T, Sohoglu E, Peterson K, Jones P, Rua C, Passamonti L, et al.
Cell Rep
. 2023 Apr;
42(5):112422.
PMID: 37099422
Humans use predictions to improve speech perception, especially in noisy environments. Here we use 7-T functional MRI (fMRI) to decode brain representations of written phonological predictions and degraded speech signals...
10.
Progression of atypical parkinsonian syndromes: PROSPECT-M-UK study implications for clinical trials
Street D, Jabbari E, Costantini A, Jones P, Holland N, Rittman T, et al.
Brain
. 2023 Mar;
146(8):3232-3242.
PMID: 36975168
The advent of clinical trials of disease-modifying agents for neurodegenerative disease highlights the need for evidence-based end point selection. Here we report the longitudinal PROSPECT-M-UK study of progressive supranuclear palsy...